230 related articles for article (PubMed ID: 23837261)
41. Patients, physicians, and clinical trials: the other side of the coins.
Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
[No Abstract] [Full Text] [Related]
42. The web of clinical trial registration obligations: have foreign clinical trials been caught?
Hathaway CR; Manthei JR; Haas JB; Meltzer ED
Food Drug Law J; 2009; 64(2):261-75. PubMed ID: 19999283
[TBL] [Abstract][Full Text] [Related]
43. Investment managers back greater transparency of clinical trials.
Hawkes N
BMJ; 2015 Jul; 351():h4002. PubMed ID: 26207007
[No Abstract] [Full Text] [Related]
44. [Transparency codex of the VFA (Association of Research-Based Pharmaceutical Companies). Why cooperation should be visible].
Laschet H
MMW Fortschr Med; 2014 Jul; 156(13):20-1. PubMed ID: 25318209
[No Abstract] [Full Text] [Related]
45. [Regulations concerning data transparency- a comparison between the USA and Europe].
Quack C
Z Evid Fortbild Qual Gesundhwes; 2011; 105(3):183-8. PubMed ID: 21530907
[TBL] [Abstract][Full Text] [Related]
46. Transparent reaction. Suppliers oppose FDA move to disclose more data.
Rhea S
Mod Healthc; 2010 Jul; 40(30):16. PubMed ID: 20695055
[No Abstract] [Full Text] [Related]
47. Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.
Herder M
CMAJ; 2012 Feb; 184(2):194-9. PubMed ID: 21876028
[No Abstract] [Full Text] [Related]
48. The economic wisdom of regulating pharmaceutical "freebies".
Fisher SH
Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416
[No Abstract] [Full Text] [Related]
49. Pharma's commitment to maintaining a clinical trial register: increased transparency or contrived public appeasement?
Falit B
J Law Med Ethics; 2005; 33(2):391-6. PubMed ID: 16083099
[No Abstract] [Full Text] [Related]
50. NerveCenter: Office of Inspector General warns NIH on lax COI oversight as many academic medical centers look inward.
Samson K
Ann Neurol; 2010 Mar; 67(3):A7-A10. PubMed ID: 20373337
[No Abstract] [Full Text] [Related]
51. How companies stall generics and keep themselves healthy.
Stolberg SG; Gerth J
N Y Times Web; 2000 Jul; ():A1, A14, A15. PubMed ID: 11785519
[No Abstract] [Full Text] [Related]
52. European ombudsman questions European Medicines Agency over AbbVie redactions.
Watson R
BMJ; 2014 Nov; 349():g6904. PubMed ID: 25406123
[No Abstract] [Full Text] [Related]
53. [Beyond "data sharing"].
Lamarca R; Herrera D
Med Clin (Barc); 2015 Jun; 144(12):548-9. PubMed ID: 25843632
[No Abstract] [Full Text] [Related]
54. More transparency for clinical trial data: The decision by the European Medicines Agency to make clinical trial reports publicly available could provide a boon for biomedical research.
Hunter P
EMBO Rep; 2015 Jan; 16(1):21-3. PubMed ID: 25476710
[No Abstract] [Full Text] [Related]
55. Pharmaceuticals and medical devices: FDA oversight.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
[No Abstract] [Full Text] [Related]
56. Informed consent elements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2011 Jan; 76(2):256-70. PubMed ID: 21261126
[TBL] [Abstract][Full Text] [Related]
57. Clinical trials registries: towards improved access to therapeutic data.
Prescrire Int; 2008 Dec; 17(98):256-9. PubMed ID: 19425275
[TBL] [Abstract][Full Text] [Related]
58. US to require public disclosure of drug and device industry's financial ties to doctors.
Epstein K
BMJ; 2012 Jan; 344():e515. PubMed ID: 22262802
[No Abstract] [Full Text] [Related]
59. College was right not to disclose deliberations about chronic fatigue treatment trial, tribunal rules.
Dyer C
BMJ; 2013 Aug; 347():f5355. PubMed ID: 23996378
[No Abstract] [Full Text] [Related]
60. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
